HK1198370A1 - Nucleic acids specifically binding cgrp - Google Patents

Nucleic acids specifically binding cgrp Download PDF

Info

Publication number
HK1198370A1
HK1198370A1 HK14111873.3A HK14111873A HK1198370A1 HK 1198370 A1 HK1198370 A1 HK 1198370A1 HK 14111873 A HK14111873 A HK 14111873A HK 1198370 A1 HK1198370 A1 HK 1198370A1
Authority
HK
Hong Kong
Prior art keywords
nucleic acids
specifically binding
acids specifically
cgrp
binding cgrp
Prior art date
Application number
HK14111873.3A
Other languages
English (en)
Chinese (zh)
Inventor
Schülzchen Simone
Purschke Werner
Jarosch Florian
Höhlig Kai
Maasch Christian
Klussmann Sven
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of HK1198370A1 publication Critical patent/HK1198370A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14111873.3A 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp HK1198370A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EPPCT/EP2012/000089 2012-01-10
EP12000105.2 2012-01-10
EP12000105 2012-01-10
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
HK1198370A1 true HK1198370A1 (en) 2015-04-10

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111873.3A HK1198370A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Country Status (14)

Country Link
US (1) US9163243B2 (enExample)
EP (1) EP2802659A1 (enExample)
JP (1) JP2015506174A (enExample)
KR (1) KR20140111704A (enExample)
CN (1) CN104136612A (enExample)
AU (1) AU2013209130A1 (enExample)
BR (1) BR112014016939A2 (enExample)
CA (1) CA2860809A1 (enExample)
HK (1) HK1198370A1 (enExample)
IL (1) IL233515A0 (enExample)
MX (1) MX2014008456A (enExample)
RU (1) RU2014132706A (enExample)
SG (1) SG11201403769YA (enExample)
WO (1) WO2013104539A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518265B2 (en) 2012-01-10 2016-12-13 Noxxon Pharma Ag C5a binding nucleic acids
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CN113383079B (zh) 2018-11-12 2024-11-19 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
WO1996005221A1 (en) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
JP4531132B2 (ja) 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
DK2431377T3 (en) 2001-10-26 2017-08-14 Noxxon Pharma Ag Modified L-nucleic acids
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
WO2003093472A2 (de) * 2002-05-06 2003-11-13 Grünenthal GmbH Cgrp bindende nukleinsäuren
MXPA05011022A (es) 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
CA2585664C (en) 2004-11-05 2014-05-20 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
EP1877069A2 (de) * 2005-05-04 2008-01-16 Noxxon Pharma AG Neue verwendung von spiegelmeren
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
EP2061901A2 (en) 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
EP2663640B1 (en) * 2011-01-10 2020-11-04 APTARION biotech AG Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

Also Published As

Publication number Publication date
RU2014132706A (ru) 2016-02-27
US9163243B2 (en) 2015-10-20
CN104136612A (zh) 2014-11-05
CA2860809A1 (en) 2013-07-18
BR112014016939A2 (pt) 2019-09-24
US20150031755A1 (en) 2015-01-29
JP2015506174A (ja) 2015-03-02
SG11201403769YA (en) 2014-07-30
EP2802659A1 (en) 2014-11-19
AU2013209130A1 (en) 2014-07-10
IL233515A0 (en) 2014-08-31
MX2014008456A (es) 2014-11-25
KR20140111704A (ko) 2014-09-19
WO2013104539A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
BR112014016939A2 (pt) ácidos nucleicos que se ligam especificamente a cgrp
BR112014016877A2 (pt) ácidos nucleicos de ligação a c5a
Murray et al. Gene duplication, loss and selection in the evolution of saxitoxin biosynthesis in alveolates
WO2017216472A3 (fr) Variants d'une adn polymérase de la famille polx
IL250539B (en) Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
HK1223625A1 (zh) 胞苷-5-甲酰胺修饰的核苷酸组合物及其相关方法
JP2018513668A5 (enExample)
EP2601293A4 (en) RNA INTERFERENCE-MEDIATED INHIBITION OF CATENINE (CADHERIN-ASSOCIATED PROTEIN) -BEETA-1 (CTNNB1) - GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
WO2007145612A8 (en) Paired end sequencing
PH12019501302A1 (en) Use of biological rna scaffolds with in vitro selection to generate robust small molecule binding aptamers for genetically encodable biosensors
EP4328303A3 (en) Novel use
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
MX2020003113A (es) Sistemas y metodos para secuenciar acido nucleico.
EP3368178A4 (en) METHOD AND SYSTEMS FOR CONTROLLING THROUGH DNA, RNA AND OTHER BIOLOGICAL MOLECULES THAT GO THROUGH NANOPORES
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
WO2008009477A3 (en) Means for inhibiting the expression of protein kinase 3
WO2013091612A3 (de) Neue aus pflanzen stammende cis-regulatorische elemente für die entwicklung pathogen-responsiver chimärer promotoren
WO2016106387A3 (en) Nucleic acid aptamers to treat histone-induced disease states
WO2015150482A8 (en) A combination product comprising a nucleic acid structure and a single-stranded nucleic acid molecule
Al-Furoukh et al. Binding to G-quadruplex RNA activates the mitochondrial GTPase NOA1
WO2010079117A3 (en) Transplastomic plants free of the selectable marker
HUE071824T2 (hu) Nukleinsav-konstruktumok VA RNS transzkripcióhoz
JP2016108250A5 (enExample)